- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC
December 5th 2025, 5:58pm
Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.
Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC
December 5th 2025, 5:45pm
Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence
December 5th 2025, 2:00pm
Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.
NDV-01 Elicits 92% CR Rate in High-Risk NMIBC
December 5th 2025, 1:00pm
Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.
Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis
December 4th 2025, 8:18pm
Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.
Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC
December 4th 2025, 7:51pm
Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.
Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025
December 4th 2025, 1:00pm
San Antonio Breast Cancer Symposium
Leading experts highlight key HER2-positive studies ahead of SABCS 2025.
TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS
December 3rd 2025, 5:10pm
Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.
Real-World Data Shows Vorasidenib Could Address Earlier Treatment Needs in IDH-Mutant Glioma
November 29th 2025, 11:00am
Society for Neuro-Oncology Annual Meeting
Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.
Vorasidenib Demonstrates Favorable Safety Profile and Disease Stability in High-Grade IDH-Mutant Gliomas
November 27th 2025, 2:00pm
Society for Neuro-Oncology Annual Meeting
Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,
Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma
November 25th 2025, 8:31pm
Society for Neuro-Oncology Annual Meeting
B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.
Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
November 24th 2025, 9:03pm
Society for Neuro-Oncology Annual Meeting
INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.
Dr Grommes on the Addition of Ibrutinib to R-MPV Induction in Newly Diagnosed PCNSL
November 24th 2025, 7:06pm
Society for Neuro-Oncology Annual Meeting
Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.
Dr Schaff on a Phase 1 Study of Copanlisib Plus Ibrutinib in Relapsed/Refractory PCNSL
November 24th 2025, 4:56pm
Society for Neuro-Oncology Annual Meeting
Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.
Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL
November 24th 2025, 4:48pm
Society for Neuro-Oncology Annual Meeting
Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.
Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors
November 24th 2025, 2:00pm
Society for Neuro-Oncology Annual Meeting
Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.
Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma
November 24th 2025, 1:00pm
Society for Neuro-Oncology Annual Meeting
Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.
18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases
November 23rd 2025, 11:20pm
Society for Neuro-Oncology Annual Meeting
18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.
Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma
November 23rd 2025, 7:07pm
Society for Neuro-Oncology Annual Meeting
Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.
Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma
November 23rd 2025, 3:20am
Society for Neuro-Oncology Annual Meeting
Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.